Currie Mark G 4

What Happened

• Mark G. Currie, a director of Ironwood Pharmaceuticals, received an award of 63,481 restricted shares on June 16, 2026. The grant is reported as transaction code "A" (award/acquisition) at $0.00 per share (total $0), reflecting a compensation grant rather than an open-market purchase.

Key Details

• Transaction date: 2026-06-16; Form 4 filed 2026-06-17 (timely).
• Shares granted: 63,481 restricted common shares; reported price: $0.00; reported value: $0.
• Shares owned following transaction: not specified in the provided filing.
• Footnote: Grant made under the Second Amended and Restated Non-employee Director Compensation Policy (effective Jan 1, 2024). The restricted shares vest in full on the date immediately preceding the annual meeting of stockholders in the next calendar year.
• Transaction type: Award/compensation (not a purchase or sale); no 10b5-1 or tax-withholding notation in the provided info.

Context

• This is a routine director compensation award. Because the shares are restricted and subject to vesting, they may not be freely tradable until they vest per the policy. Such awards reflect customary board compensation and are not by themselves a directional buy/sell signal.